Date Title and Summary Additional Formats
Dec 05, 2024
PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024
Nov 27, 2024
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
Nov 18, 2024
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
Nov 13, 2024
PHAXIAM Reports Third-Quarter 2024 Financial Information
Nov 08, 2024
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024
Nov 04, 2024
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
Oct 10, 2024
Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024
Oct 09, 2024
PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study
Sep 25, 2024
PHAXIAM Provides Business and Financial Update For the First Half of 2024
Jul 03, 2024
Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024